Literature DB >> 22500026

Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.

Mari Okayasu1, Mai Nakayachi, Chiyomi Hayashida, Junta Ito, Toshio Kaneda, Masaaki Masuhara, Naoto Suda, Takuya Sato, Yoshiyuki Hakeda.   

Abstract

Osteoporosis is associated with both atherosclerosis and vascular calcification attributed to hyperlipidemia. However, the cellular and molecular mechanisms explaining the parallel progression of these diseases remain unclear. Here, we used low-density lipoprotein receptor knockout (LDLR(-/-)) mice to elucidate the role of LDLR in regulating the differentiation of osteoclasts, which are responsible for bone resorption. Culturing wild-type osteoclast precursors in medium containing LDL-depleted serum decreased receptor activator of NF-κB ligand (RANKL)-induced osteoclast formation, and this defect was additively rescued by simultaneous treatment with native and oxidized LDLs. Osteoclast precursors constitutively expressed LDLR in a RANKL-independent manner. Osteoclast formation from LDLR(-/-) osteoclast precursors was delayed, and the multinucleated cells formed in culture were smaller and contained fewer nuclei than wild-type cells, implying impaired cell-cell fusion. Despite these findings, RANK signaling, including the activation of Erk and Akt, was normal in LDLR(-/-) preosteoclasts, and RANKL-induced expression of NFATc1 (a master regulator of osteoclastogenesis), cathepsin K, and tartrate-resistant acid phosphatase was equivalent in LDLR-null and wild-type cells. In contrast, the amounts of the osteoclast fusion-related proteins v-ATPase V(0) subunit d2 and dendritic cell-specific transmembrane protein in LDLR(-/-) plasma membranes were reduced when compared with the wild type, suggesting a correlation with impaired cell-cell fusion, which occurs on the plasma membrane. LDLR(-/-) mice consistently exhibited increased bone mass in vivo. This change was accompanied by decreases in bone resorption parameters, with no changes in bone formation parameters. These findings provide a novel mechanism for osteoclast differentiation and improve the understanding of the correlation between osteoclast formation and lipids.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22500026      PMCID: PMC3365955          DOI: 10.1074/jbc.M111.323600

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

1.  Receptor activator of NF-κB ligand-dependent expression of caveolin-1 in osteoclast precursors, and high dependency of osteoclastogenesis on exogenous lipoprotein.

Authors:  Naoto Hada; Mari Okayasu; Junta Ito; Mai Nakayachi; Chiyomi Hayashida; Toshio Kaneda; Noritaka Uchida; Takamichi Muramatsu; Chihiro Koike; Masaaki Masuhara; Takuya Sato; Yoshiyuki Hakeda
Journal:  Bone       Date:  2011-10-30       Impact factor: 4.398

2.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src.

Authors:  B R Wong; D Besser; N Kim; J R Arron; M Vologodskaia; H Hanafusa; Y Choi
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

Review 3.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

4.  Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).

Authors:  Ya-Hui Chiu; Kofi A Mensah; Edward M Schwarz; Yawen Ju; Masahiko Takahata; Changyong Feng; Loralee A McMahon; David G Hicks; Ben Panepento; Peter C Keng; Christopher T Ritchlin
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

5.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

6.  DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells.

Authors:  F C Hartgers; J L Vissers; M W Looman; C van Zoelen; C Huffine; C G Figdor; G J Adema
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

7.  Atherogenic high-fat diet reduces bone mineralization in mice.

Authors:  F Parhami; Y Tintut; W G Beamer; N Gharavi; W Goodman; L L Demer
Journal:  J Bone Miner Res       Date:  2001-01       Impact factor: 6.741

8.  Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).

Authors:  Je-Tae Woo; Hiroshi Nakagawa; Annette M Krecic; Kazuo Nagai; Andrew D Hamilton; Said M Sebti; Paula H Stern
Journal:  Biochem Pharmacol       Date:  2005-01-01       Impact factor: 5.858

9.  Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women.

Authors:  L B Tankò; Y Z Bagger; C Christiansen
Journal:  Calcif Tissue Int       Date:  2003-07       Impact factor: 4.333

10.  Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins.

Authors:  E Luegmayr; H Glantschnig; G A Wesolowski; M A Gentile; J E Fisher; G A Rodan; A A Reszka
Journal:  Cell Death Differ       Date:  2004-07       Impact factor: 15.828

View more
  25 in total

Review 1.  Low-Density Lipoprotein Receptor-Related Proteins in Skeletal Development and Disease.

Authors:  Tao Yang; Bart O Williams
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

Review 2.  Metabolic reprogramming in osteoclasts.

Authors:  Kyung-Hyun Park-Min
Journal:  Semin Immunopathol       Date:  2019-09-24       Impact factor: 9.623

3.  Osteocytes produce interferon-β as a negative regulator of osteoclastogenesis.

Authors:  Chiyomi Hayashida; Junta Ito; Mai Nakayachi; Mari Okayasu; Yoko Ohyama; Yoshiyuki Hakeda; Takuya Sato
Journal:  J Biol Chem       Date:  2014-03-07       Impact factor: 5.157

4.  Evaluation of serum and salivary PCSK9 and IL6 and its association with periodontal inflammation and atherosclerotic cardiovascular diseases.

Authors:  Roshan R Rughwani; Priyanka K Cholan; Dhayanand John Victor; Paavai Ilango; Sanjay M Cherian; Rajkumar N Rughwani; Anupama Tadepalli
Journal:  J Oral Biol Craniofac Res       Date:  2022-08-17

5.  Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

Authors:  Toshifumi Sugatani; Olga A Agapova; Yifu Fang; Alycia G Berman; Joseph M Wallace; Hartmut H Malluche; Marie-Claude Faugere; William Smith; Victoria Sung; Keith A Hruska
Journal:  Kidney Int       Date:  2016-09-22       Impact factor: 10.612

6.  Osteoclast fusion and regulation by RANKL-dependent and independent factors.

Authors:  Lianping Xing; Yan Xiu; Brendan F Boyce
Journal:  World J Orthop       Date:  2012-12-18

Review 7.  Lipids in the Bone Marrow: An Evolving Perspective.

Authors:  Elizabeth Rendina-Ruedy; Clifford J Rosen
Journal:  Cell Metab       Date:  2019-10-24       Impact factor: 27.287

8.  Cartilage-specific ablation of site-1 protease in mice results in the endoplasmic reticulum entrapment of type IIb procollagen and down-regulation of cholesterol and lipid homeostasis.

Authors:  Debabrata Patra; Elizabeth DeLassus; Guosheng Liang; Linda J Sandell
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

Review 9.  Physiologic and pathologic effects of dietary free fatty acids on cells of the joint.

Authors:  Natalia S Harasymowicz; Amanda Dicks; Chia-Lung Wu; Farshid Guilak
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

10.  Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration.

Authors:  I Prieto-Potín; J A Roman-Blas; M J Martínez-Calatrava; R Gómez; R Largo; Gabriel Herrero-Beaumont
Journal:  Arthritis Res Ther       Date:  2013-08-13       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.